{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:21Z","timestamp":1790346681757,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:00:00Z","timestamp":1555459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C16708\/A21855"],"award-info":[{"award-number":["C16708\/A21855"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yorkshire Cancer Research","award":["L374RA"],"award-info":[{"award-number":["L374RA"]}]},{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["KKL1071"],"award-info":[{"award-number":["KKL1071"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ymthe.2019.04.008","type":"journal-article","created":{"date-parts":[[2019,4,14]],"date-time":"2019-04-14T01:16:48Z","timestamp":1555204608000},"page":"1139-1152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition"],"prefix":"10.1016","volume":"27","author":[{"given":"Victoria A.","family":"Jennings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina B.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa M.S.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Migneco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Peach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Dewar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardev","family":"Pandha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Vile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan A.","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Errington-Mais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.04.008_bib1","doi-asserted-by":"crossref","first-page":"102617","DOI":"10.18632\/oncotarget.18309","article-title":"Review: Oncolytic virotherapy, updates and future directions","volume":"8","author":"Fountzilas","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2019.04.008_bib2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2010.495383","article-title":"Herpes simplex virus oncolytic vaccine therapy in melanoma","volume":"10","author":"Sivendran","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib3","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2174\/138920112800958904","article-title":"Recent Clinical Experience With Oncolytic Viruses","volume":"13","author":"Donnelly","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2019.04.008_bib5","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.04.008_bib6","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib8","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/fon.10.66","article-title":"OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma","volume":"6","author":"Kaufman","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib9","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib10","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","article-title":"Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.04.008_bib11","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/13543784.2010.510514","article-title":"The clinical development of histone deacetylase inhibitors as targeted anticancer drugs","volume":"19","author":"Marks","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2019.04.008_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biocel.2018.03.004","article-title":"HDAC inhibitors as epigenetic regulators for cancer immunotherapy","volume":"98","author":"Conte","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2018.07.057","article-title":"Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer","volume":"835","author":"Heers","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib16","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/mt.2008.155","article-title":"Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses","volume":"16","author":"Otsuki","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cytogfr.2010.03.002","article-title":"Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells","volume":"21","author":"Nguyen","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2019.04.008_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omto.2017.05.002","article-title":"Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma","volume":"5","author":"Jaime-Ramirez","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2019.04.008_bib19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/mt.2012.265","article-title":"HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy","volume":"21","author":"Bridle","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib20","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3390\/v8010009","article-title":"Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade","volume":"8","author":"Marchini","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2019.04.008_bib21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/emmm.201302796","article-title":"Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas","volume":"5","author":"Li","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2019.04.008_bib22","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.4049\/jimmunol.0901074","article-title":"Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus","volume":"183","author":"Prestwich","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib23","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ijc.27918","article-title":"Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells","volume":"132","author":"Adair","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2019.04.008_bib24","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2015.88","article-title":"Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia","volume":"29","author":"Parrish","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2019.04.008_bib25","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1158\/1078-0432.CCR-08-0831","article-title":"Tumor infection by oncolytic reovirus primes adaptive antitumor immunity","volume":"14","author":"Prestwich","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.04.008_bib26","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","article-title":"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication","volume":"15","author":"Prestwich","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2019.04.008_bib27","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/gt.2008.58","article-title":"Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma","volume":"15","author":"Errington","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib28","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.4049\/jimmunol.180.9.6018","article-title":"Reovirus activates human dendritic cells to promote innate antitumor immunity","volume":"180","author":"Errington","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/leu.2008.354","article-title":"Effective in\u00a0vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate","volume":"23","author":"Poggi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2019.04.008_bib30","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.008_bib31","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JVI.05545-11","article-title":"The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5\/T-BET signaling and generation of gamma interferon","volume":"86","author":"Alvarez-Breckenridge","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/mt.2015.143","article-title":"Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus","volume":"24","author":"Taipale","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib34","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/nm.3013","article-title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors","volume":"18","author":"Alvarez-Breckenridge","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2019.04.008_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fonc.2014.00217","article-title":"Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines","volume":"4","author":"Tai","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib36","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1099\/vir.0.063990-0","article-title":"Modulation of the host microenvironment by a common non-oncolytic mouse virus leads to inhibition of plasmacytoma development through NK cell activation","volume":"95","author":"Thirion","year":"2014","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib37","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2019.04.008_bib38","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/mt.2011.147","article-title":"Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy","volume":"19","author":"Kottke","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib39","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/mt.2012.137","article-title":"An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance","volume":"20","author":"Cerullo","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1525-0016(03)00120-5","article-title":"Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib41","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1182\/blood-2015-04-639088","article-title":"UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells","volume":"127","author":"Samudio","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.008_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ijc.25319","article-title":"Adjuvant effects of formalin-inactivated HSV through activation of dendritic cells and inactivation of\u00a0myeloid-derived suppressor cells in cancer immunotherapy","volume":"128","author":"Ohkusu-Tsukada","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2019.04.008_bib43","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/ijc.31026","article-title":"Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity","volume":"141","author":"Schwaiger","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2019.04.008_bib44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gutjnl-2016-312009","article-title":"Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer","volume":"67","author":"Samson","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ymthe.2019.04.008_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1084\/jem.20041961","article-title":"Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs","volume":"202","author":"Yoneyama","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2019.04.008_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fmicb.2015.00557","article-title":"A subset of human plasmacytoid dendritic cells expresses CD8\u03b1 upon exposure to herpes simplex virus type 1","volume":"6","author":"Schuster","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib47","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2005-04-1737","article-title":"Virus-stimulated plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T\u00a0cells","volume":"107","author":"Kawamura","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.008_bib48","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbagrm.2010.05.008","article-title":"Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions","volume":"1799","author":"Marks","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2019.04.008_bib49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cgt.2008.81","article-title":"The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells","volume":"16","author":"Katsura","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2019.04.008_bib50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/rmv.690","article-title":"How to control an infectious bead string: nucleosome-based regulation and targeting of herpesvirus chromatin","volume":"21","author":"Nevels","year":"2011","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib51","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1128\/JVI.78.3.1063-1068.2004","article-title":"Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?","volume":"78","author":"Smiley","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib52","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1128\/JVI.01350-14","article-title":"The herpes simplex virus 1 virion host shutoff protein enhances translation of viral late mRNAs by preventing mRNA overload","volume":"88","author":"Dauber","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib53","doi-asserted-by":"crossref","first-page":"12030","DOI":"10.1128\/JVI.01575-08","article-title":"Herpes simplex virus ICP0 promotes both histone removal and acetylation on viral DNA during lytic infection","volume":"82","author":"Cliffe","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2019.04.008_bib54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/phar.1912","article-title":"Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review","volume":"37","author":"Riker","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ymthe.2019.04.008_bib55","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2015.1035441","article-title":"Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"53","author":"Ghannoum","year":"2015","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.ymthe.2019.04.008_bib56","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.91.9.3515","article-title":"Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T\u00a0cells infiltrating into tumor","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.04.008_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jcp.1041070111","article-title":"Studies on a human melanoma cell line: effect of cell crowding and nutrient depletion on the biophysical and kinetic characteristics of the cells","volume":"107","author":"Sheridan","year":"1981","journal-title":"J.\u00a0Cell. Physiol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619301741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619301741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:55:07Z","timestamp":1761501307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619301741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1525001619301741"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.008","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors.","name":"copyright","label":"Copyright"}]}}